Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.42 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.42 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.42 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.42 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.42 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30952855 | 1.00 | RAPGEF3 (0.47) | RAPGEF3ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL17935270 | 0.90 | MAPT (0.51) | RAPGEF3ALDH1A1MAPTKDM4ENPC1 | |
| SCHEMBL1732950 | 0.86 | NPC1 (0.58) | ALDH1A1LMNAMAPTKDM4ENPC1 | |
| SCHEMBL31472484 | 0.85 | PTGS2 (0.53) | RAPGEF3ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL6986185 | 0.85 | PTGS2 (0.53) | RAPGEF3ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL20982550 | 0.83 | MAPT (0.48) | ALDH1A1LMNAMAPTNPC1RAB9A | |
| SCHEMBL16408222 | 0.83 | MAPT (0.54) | RAPGEF3ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL30680765 | 0.83 | MAPT (0.54) | RAPGEF3ALDH1A1LMNAMAPTKDM4E | |
| SCHEMBL1941520 | 0.82 | NPC1 (0.41) | RAPGEF3ALDH1A1LMNAMAPTNPC1 | |
| SCHEMBL27399229 | 0.82 | MAPT (0.43) | ALDH1A1LMNAMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630414-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | Captor Therapeutics S.A. (PL) | 2025-10-15 | — | — | EP | disclosed |
| EP-4630415-A1 | TARGETED PROTEIN DEGRADATION USING PRODRUGS OF BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | Captor Therapeutics S.A. (PL) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024121259-A1 | TARGETED PROTEIN DEGRADATION USING PRODRUGS OF BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024121256-A1 | TARGETED PROTEIN DEGRADATION USING BIFUNCTIONAL COMPOUNDS THAT BIND UBIQUITIN LIGASE AND TARGET MCL-1 PROTEIN | CAPTOR THERAPEUTICS S.A. (PL) | 2024-06-13 | — | — | WO | disclosed |
| EP-3298022-B1 | NOVEL ANNELATED PHENOXYACETAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2019-06-05 | — | — | EP | disclosed |
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-19 | — | — | US | disclosed |
| US-20180002312-A1 | TETRA- AND PENTASUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2018-01-04 | — | — | US | disclosed |
| US-20170313732-A1 | NOVEL ANNELATED PHENOXYACETAMIDES | BOEHRINGER INGELHEIM INT (DE) | 2017-11-02 | — | — | US | disclosed |
| WO-2017028927-A1 | NOVEL ANNELATED PHENOXYACETAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-23 | — | — | WO | disclosed |
| US-20170050992-A1 | NOVEL ANNELATED PHENOXYACETAMIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-02-23 | — | — | US | disclosed |
| WO-2016113169-A1 | TETRA- AND PENTASUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-07-21 | — | — | WO | disclosed |
| US-7816540-B2 | Carboxyl- or hydroxyl-substituted benzimidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2010-10-19 | — | — | US | disclosed |
| EP-2225221-A2 | CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-08 | — | — | EP | disclosed |
| WO-2009080555-A2 | CARBOXYL- OR HYDROXYL- SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-07-02 | — | — | WO | disclosed |
| US-20090163552-A1 | CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180105512-A1 | SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | TPSD1, TPSAB1, TMSB4X | RAPGEF3 4414/4885ALDH1A1 2197/4885LMNA 284/4885 |
| US-20170313732-A1 | NOVEL ANNELATED PHENOXYACETAMIDES | EP300, NAT1, AADAC | RAPGEF3 1788/4885ALDH1A1 113/4885LMNA 4370/4885 |
| US-20180002312-A1 | TETRA- AND PENTASUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, F12, HRH4 | RAPGEF3 4382/4885ALDH1A1 1331/4885LMNA 1253/4885 |
| US-20170050992-A1 | NOVEL ANNELATED PHENOXYACETAMIDES | EP300, NAT1, AADAC | RAPGEF3 1617/4885ALDH1A1 144/4885LMNA 4306/4885 |
| US-20090163552-A1 | CARBOXYL- OR HYDROXYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES | NR1H4, GPBAR1, SLC10A1 | RAPGEF3 2628/4885ALDH1A1 352/4885LMNA 4664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.